Results from animal models and clinical trials suggested that Fcg-receptor-mediated effector mechanisms are essential for the activity of individual therapeutic antibodies. [9] [10] In patients treated with rituximab, in particular, the homozygous expression of the FcgRIIIa-158V/V allotype, which has higher binding affinity for Immunoglobulin G (IgG) than the FcgRIIIa-158F/F variant, was correlated with improved response rates and overall survival. 11 These observations suggest a substantial contribution of FcgRIIIapositive effector cells, such as natural killer (NK) cells and macrophages, in antibody therapy. Therefore binding of Fc domains to activating Fcg-receptors was increased, for example, by modifying the protein backbone. 12 These modifications enhanced the antibody's ability to induce effector cell-mediated killing of tumor cells. The Fc domain-engineering XmAb technology has recently been applied to a humanized, affinity maturated CD19 antibody, MOR208 (formerly designated XmAb5574). 7 MOR208 inhibited tumor growth in mouse xenograft models, and Fc-engineering was essential for B-cell depletion in nonhuman primates. 13 Recently, we and others have demonstrated that MOR208 potently triggered antibodydependent cell-mediated cytotoxicity (ADCC) of various CD19-positive tumor cell lines and primary tumor cells from patients with different B-cell malignancies including chronic lymphocytic leukemia or adult ALL. 7, [14] [15] These results motivated us to characterize the activity of MOR208 against ALL in more detail using primary ALL cells isolated from both adult and pediatric patients (Supplementary Table 1 ). To study the clinically relevant, Fc-mediated effector functions, we investigated the contributions of various effector cells, as well as complement, to the cytotoxic profile of MOR208 using standard 51 Cr release experiments ( Figure 1a ; further technical information is provided in the Supplementary Materials and methods section). The corresponding native CD19 IgG 1 antibody containing a wild-type Fc domain Letters to the Editor was included for comparison. MOR208 and the CD19 IgG 1 induced killing of ALL blasts in the presence of mononuclear cells (MNC), but failed to trigger cytotoxic activities of polymorphonuclear neutrophils. Moreover, the CD19 antibodies were unable to trigger complement-dependent cytotoxicity ( Figure 1a) . As the MNC fractions contained two FcgR-expressing cytotoxic effector cell populations, that is, NK cells and monocytes, which both may have contributed to target cell elimination, isolated NK cells and monocytes were separately assayed as the cytotoxic effectors of CD19 antibodies. Both MOR208 and the CD19 IgG 1 were only able to trigger ADCC by NK cells, but not by monocytes (Figure 1b) . Consequently, the CD19 antibodies bound to ALL blasts activated Letters to the Editor NK cells as verified by analyzing the induced expression of the activation marker CD69 by flow cytometry (Figure 1c ). Also, MOR208 activated a higher percentage of NK cells than the CD19 IgG 1 . The extent of lysis induced by both CD19 antibodies rose with increasing effector-target (E:T) cell ratios (Figure 1d ). At all E:T cell ratios tested, MOR208 was more effective than its IgG 1 analog. Thus, NK cell-mediated ADCC was identified as the relevant effector mechanism exerted by MOR208 in vitro.
The ADCC activity of MOR208 against malignant ALL cells from both adult and pediatric ALL patients was quantified (Supplementary Table 1 ; Figures 2a and b) . The disparate ALL samples displayed diverse genetic aberrations associated with unfavorable prognosis including translocations involving the mixed lineage leukemia gene, and different maturation stages (Supplementary Table 1 ). MOR208 was able to induce ADCC against ALL blasts from both adult and pediatric patients using NK cells as effector cells, and exerted cytotoxicity against all samples tested (Figures 2a and b) . Rituximab, which was included for comparison, exhibited no cytotoxic effect upon these CD20-negative ALL samples. MOR208 mediated lysis in a dosedependent manner and was active at very low antibody concentrations exerting EC50 values at B4 ng/ml (B26 pmol/l). In all cases MOR208 had a higher ADCC capacity than the non-Fcengineered CD19 antibody, as reflected by both lower EC50 values and higher maximum extents of lysis (Figure 2c ). This improved ADCC potential was observed irrespective of the FcgRIII-V/F allotype of the applied NK cells at position 158 (Figure 2d ).
NK cell cytotoxicity is impaired against autologous cells due to interactions between KIR on NK cells and HLA class I molecules on the target cells. To determine whether MOR208 was able to overcome KIR-mediated inhibition, ADCC reactions were performed in an autologous setting (Figure 2e ). NK cells were prepared from the peripheral blood of an ALL patient on day 20 after the first course of consolidation chemotherapy. At that time point considerable amounts of malignant blasts were still detectable, and accounted for 40% of peripheral leukocytes (data not shown). It is impressive that MOR208 induced ADCC with NK cells derived from the patient, and mediated lysis of primary autologous ALL blasts with high HLA class I expression. This indicated that the activating signals of the Fc-engineered antibody were strong enough to overcome HLA class I-mediated NK cell inhibition.
After relapse, the patient received a transplant of allogeneic hematopoietic progenitor cells. Complete donor chimerism was achieved as verified by short tandem repeat analysis at days 21, 78 and 86 post transplantation. NK cells rapidly reconstituted and reached a normal absolute value of 117 cells/ml as measured by day 40 post transplantation (data not shown). At day 65, the CD56-positive effector cells from peripheral blood were isolated. In ADCC reactions using these stem cell donor-derived effector cells, MOR208 mediated measurable ADCC (Figure 2e) . Hence, MOR208 exerted biological activity both with autologous and stem cell donor-derived NK cells isolated from the patient.
Our experiments demonstrate that MOR208 exhibits enhanced cytotoxicity, relative to a native non-engineered anti-CD19 antibody, in vitro using patient-derived material. Hence, it may represent a promising therapeutic modality for the treatment of pediatric as well as adult B-ALL patients. Application of MOR208 may be especially promising for the eradication of minimal residual disease cells in a post transplantation setting when high numbers of NK effector cells have recovered resulting in high effector-to-target ratios.
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3 TCR rearrangements were assessed by multiplex PCR with subsequent fragment analysis. 6 Dichotomous variables were compared between different groups using the w 2 -test and continuous variables by Student's t-test. Results were considered significant at Po0.05. All the reported P-values are two-sided. No adjustments for multiple comparisons were performed. SPSS version 19.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. Overall, in 40/55 T-LGL leukemia cases (72.7%), 41 STAT3 mutations were detected. All mutations were missense mutations. Six different mutations were observed (Figure 1 ). Tyr640Phe (n ¼ 18) and Asp661Tyr (n ¼ 13) accounted for 75.6% of all mutations detected. One patient harbored two mutations (Asn647Ile and Tyr640Phe). We also detected a Ile659Leu in one patient, which has not been described previously. 3, 4 There was no association of STAT3 mutations with age, sex and peripheral blood counts in T-LGL leukemia cases (Table 1) . Cases with STAT3 mutations had a stronger expression of CD3 (percentage positive cells, 76 ± 20% vs 58 ± 22%, P ¼ 0.01) and TCRab (68±19% vs 48±20%, P ¼ 0.004). This is probably explained by the significantly elevated clonal size in STAT3-mutated cases compared with STAT3 wild-type cases (percentage positive cells, 31 ± 16% vs 16 ± 13%, P ¼ 0.006). Furthermore, we correlated STAT3 mutation load to clonal size as evaluated by immunophenotyping by Spearman's rank correlation and found a significant positive correlation (correlation coefficient ¼ 0.573, Po0.001). However, the detection of STAT3 mutations was not limited by the size of the pathological T-cell clone, as we were able to detect STAT3 mutations in clones as small as 6% as determined by immunophenotyping. Furthermore, the cohort also contained patients with clonal expansion of T-LGL cells (clonal size up to 73%) that were negative for STAT3 mutations. In addition, we validated nine STAT3 unmutated samples with pathological T-cell clones sizes of 1%-15% by a more sensitive next-generation sequencing approach (Roche 454, Roche Applied Science, Branford, CT, USA) and discovered only one additional STAT3-mutated patient. This patient had a T-cell clone size of 10% and a STAT3 mutation load of 3%. TCR gene usage did not differ between the STAT3-mutated and unmutated cases.
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